Triple Revenue Growth Rate for Transplant Molecular Testing, According to Report

Press Release
May 3, 2017
Bookmark and Share
Rockville (MD), May 3, 2017 — Kalorama Information notes that transplant diagnostics is seeing revenue growth of nine percent next year and this is projected to continue to 2021. Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Molecular testing technologies are well-suited for this task. This according to a new report from healthcare-only market research publisher Kalorama Information. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. The finding was made in the firm’s report Transplant Matching Molecular Diagnostics.

“Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago,” said Bruce Carlson, Publisher of Kalorama Information. “It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate.”

The report said the global market for molecular transplant diagnostics is estimated at over three hundred million at an average annual rate of growth of 9%. Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the United States each year. The large size of the U.S. market is sustained by demand for high resolution molecular HLA typing, including sequencing-based methods. More than 30,000 solid organ transplants and around 18,000 HSCTs are performed each year in Europe. Transplant volumes continue to grow at a faster pace in Europe than in the United States as Eastern European countries and other less mature markets perform more solid organ transplants and HSCTs. This is driving sales of test products.

The United States is the largest market for leading molecular transplant diagnostics companies Thermo Fisher Scientific, CareDx (Olerup brand), and Immucor (LIFECODES brand).

Kalorama’s report, Transplant Matching Molecular Diagnostics Market provides:

  • Global Market Forecast to 2021
  • Global Molecular Transplant Procedure Volumes, 2016 to 2021
  • Global Market Share by Vendor

The report can be found at: https://www.kaloramainformation.com/Transplant-Matching-Molecular-10819543/.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama’s website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.

800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >

Live Chat Software
Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Home About Us My Account Personal Library Contact Us
Copyright © 2017 MarketResearch.com, Inc. All Rights Reserved.
Kalorama Information - A division of Market Research Group, LLC
7/27/2017 - 141
Contact Us: 800.298.5603 (U.S.)
or +1.240.747.3096 (Int'l)
Hours: Monday - Thursday: 3:00am - 6:30pm EST
Fridays: 3:00am - 5:30pm EST